ankylosing spondylitis

Fenbufen (Lederfen) is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Upadacitinib (ABT-494) is a highly potent, selective, and orally active JAK1 inhibitor with an IC₅₀ of 43 nM; its selectivity for JAK1 is approximately 74 times that for JAK2. Upadacitinib is being investigated for the treatment of autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis.

Aceclofenac (Preservex) is a non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties.

Phenylbutazone (Butazolidine) is a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis.

Salazosulfamide has shown potential in the treatment of ankylosing spondylitis, according to research studies.

IL17A-IN-1 (Compound 72) is an orally active inhibitor of Interleukin 17A. This compound is applicable in research related to inflammatory and autoimmune diseases, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and cancer.

Simepdekinra (Compound 221) is a potent IL-17A modulator with IC₅₀ values ≤10 nM for IL-17A/A HEK-Blue cells and 10–100 nM for IL-17A/F HEK-Blue cells, suitable for studying psoriasis, ankylosing spondylitis, and psoriatic arthritis.

Azapropazone is anti-inflammatory agent. Azapropazone has uricosuric properties used to treat rheumatoid arthritis and ankylosing spondylitis. Azapropazone lowered plasma uric acid but exerted only a modest and variable uricosuric effect without altering

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).

(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor and an isomer of Elsubrutinib, suitable for inflammation research.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Gumokimab (AK 111) is a humanized monoclonal antibody designed to specifically target interleukin-17A (IL-17A). it functions by competitively inhibiting the binding of IL-17A to its cognate receptor, thereby blocking downstream pro-inflammatory signaling, Gumokimab is a candidate for therapeutic research in psoriasis and ankylosing spondylitis.

Seniprutug is a humanized monoclonal antibody targeting T cell receptor beta variable 9 (TRBV9). Seniprutug selectively depletes pathogenic T cell clones expressing TRBV9 via antibody-dependent cellular cytotoxicity (ADCC), representing a highly promising precision targeted therapeutic strategy for studying autoimmune diseases such as ankylosing spondylitis.

Emzotamig is a monoclonal antibody inhibitor targeting tumor necrosis factor (TNF). It holds potential for research on autoimmune diseases related to the overexpression of TNF, such as rheumatoid arthritis and ankylosing spondylitis.

Phenylbutazone-13C12 is the 13C12-labeled version of Phenylbutazone. Phenylbutazone (T1432) serves as an effective reducing cofactor for prostaglandin H synthase (PHS) peroxidase. It is recognized as a hepatotoxin and classified as a non-steroidal anti-inflammatory drug (NSAID). Additionally, Phenylbutazone (T1432) induces the expression of muscleblind-like protein 1 (MBNL1) and holds potential for research in ankylosing spondylitis.

Phenylbutazone (diphenyl-D10) is a deuterated form of Phenylbutazone. It serves as a reductive cofactor for prostaglandin H synthase (PHS) peroxidase and is classified as a hepatotoxin and a nonsteroidal anti-inflammatory drug (NSAID). Phenylbutazone (T1432) also induces the expression of muscleblind-like protein 1 (MBNL1) and shows potential for research in ankylosing spondylitis.

Phenylbutazone (Standard) is the standard substance of Phenylbutazone, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Phenylbutazone (Butazolidine) is a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis.